durvalumab + tremelimumab + azacitidine

This is a **combination regimen** composed of three drugs: - **Durvalumab**, a monoclonal antibody which inhibits programmed death-ligand 1 (PD-L1), blocking an immune checkpoint interaction with PD-1 and enhancing antitumor T-cell responses. - **Tremelimumab**, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which inhibits another immune checkpoint, leading to T cell activation and proliferation. - **Azacitidine**, a small molecule DNA methyltransferase inhibitor (hypomethylating agent), which induces DNA hypomethylation and direct cytotoxicity in abnormal hematopoietic cells. This drug combination has been under investigation primarily for **myelodysplastic syndrome (MDS) after failure of prior hypomethylating agent treatment**, and also in clinical trials for **head and neck squamous cell carcinoma**. Early-phase trials emphasized safety and pharmacokinetics. The combination has shown tolerability but limited efficacy and no confirmed complete or partial responses in MDS. The regimen leverages synergistic immune activation and epigenetic modulation for potential antitumor effects[1][2][4][7][8].

Brand names

Imfinzi (durvalumab)Imjudo (tremelimumab)

Other names

durvalumab + tremelimumab + azacitidine